Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

In this study, patients with active lymphocytic cicatricial alopecia showed significant improvement using a three-stage treatment regimen involving Tofacitinib, Apremilast, and Crisaborole, with 93.5% experiencing marked improvement and only three mild adverse events reported.

This study developed a new spectrophotometric method to accurately measure finasteride levels in pharmaceutical formulations using a reaction with NBD-CL.

A new food supplement was highly effective in curing hair loss in young men.

Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.

In this study, researchers assessed the physical-chemical and microbiological stability of various pharmaceutical ingredients in the vehicle TrichoSolTM, finding differing beyond-use dates for the compounds, such as 180 days for cetirizine hydrochloride, but only 90 days for progesterone at higher concentrations.

Brepocitinib reduces interferon signaling in hidradenitis suppurativa patients.

The flutamide-loaded hydrogel is a promising, skin-friendly treatment for acne and hair loss, potentially requiring less frequent application.

This study developed a Neusilin® US2-based solid self-nanoemulsifying drug delivery system for finasteride that showed improved stability and drug delivery, with complete dissolution comparable to standard Propecia® tablets.

In this study, the researchers reported that women with diffuse telogen alopecia who took Wolvit® (biotin 5 mg) daily for 3 months showed a significant decrease in hair in the telogen phase and an increase in hair thickness and growth speed.

In this study, researchers assessed the stability of various formulations in the TrichoConcept™ line for customized alopecia treatment. They found that the combinations remained stable from 14 to 180 days, supporting the use of these vehicles for enhancing therapeutic outcomes in hair loss treatments.

This study reported that VCP combination chemotherapy achieved a complete response in 53% of advanced non-Hodgkin's lymphoma patients, although more intensive treatment may be needed for improved outcomes.

This study found that both fluoxetine and clomipramine are effective in treating psychogenic triggers of acral lick dermatitis in dogs, with fluoxetine leading to quicker recovery and lower recurrence rates, while clomipramine showed better overall recovery rates but was associated with fewer side effects.